Using the non-redundant pan-cancer studies database, we established that patients with high TBXA2R expressing tumors have substantially poorer outcomes concerning progress free (29.49 vs. 58.72 months; p = 2.218 × 10−3) and disease free (55.04 vs. 140.90 months; p = 0.0442) survival (Figure 3B,C) but not overall survival (Figure 3A) compared to patients with low expression. This evidence concerns the gene TBXA2R and cancer.